Topline data were announced from two phase 3 studies evaluating MR-107A-02 for the treatment of moderate to severe acute pain.

Increased risk for attacks seen in women younger than 35 years, those with eosinophilia, those with lower corticosteroid use.

The prescription device is a wearable belt that includes a motor designed to transmit low amplitude, high frequency vibration to the spine and hips.

The Food and Drug Administration (FDA) has cleared the Jewel ® Patch Wearable Cardioverter Defibrillator (Patch-WCD) for adult patients aged 18 years and older who are at risk for sudden cardiac ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.